Table 1.
Clinical information of the liver tumor patients enrolled in this study.
| Variable | Malignant liver tumors (n=66) | Benign liver tumors (n=79) |
|---|---|---|
| Age, yr | 53 (29–83) | 48 (23–70) |
| Sex | ||
| Male | 52 | 60 |
| Female | 14 | 19 |
| Set | ||
| Training set | 43 | 52 |
| Validation set | 23 | 27 |
| Diagnostic methods | ||
| MRI | 66 | 79 |
| Histopathology | 36 | 9 |
| Etiology | ||
| HBV | 48 | 52 |
| HCV | 13 | 17 |
| Others | 5 | 10 |
| Laboratory data | ||
| Bilirubin (μmol/L) | 18.5 (3.6–293.9) | 13.3 (2.5–193.4) |
| ALT (U/L) | 35 (9–1194) | 27 (9–118) |
| AST (U/L) | 44 (10–930) | 27 (11–99) |
| Albumin (g/L) | 36.4±5.5 | 39.3±5.9 |
ALT – alanine aminotransferase; AST – aspartate aminotransferase. Data was shown as median (range) or mean ±SD if normally distributed.